Darling Ingredients (DAR) Barclays 40th Annual Energy-Power Conference summary
Event summary combining transcript, slides, and related documents.
Barclays 40th Annual Energy-Power Conference summary
10 Sep, 2026Margin outlook and regulatory environment
Supportive renewable diesel margins expected through 2027, underpinned by strong RVO mandates and constructive RIN S&D balance.
Reallocation of small refinery exemptions likely to be addressed by year-end, with rulemaking and comment periods extending into 2028 discussions.
Limited renewable diesel imports due to loss of PTC eligibility and tariffs, with no significant import changes anticipated through 2027.
Policy-driven regional dislocations and tariffs are supporting North American fat prices and margins.
Industry capacity and ag productivity are expected to keep pace with incremental RVO growth through 2029.
Strategic initiatives and business segments
Expansion into health and wellness markets via the Nextida line, leveraging clinical trials and science-backed claims for higher-margin growth.
Collagen and peptide products are gaining rapid consumer and institutional adoption, with strong momentum in sales and brand recognition.
Strategy focuses on ingredient sales to CPG companies, supported by peer-reviewed studies and clinical validation.
Margin expansion in the food segment is expected as volumes and scientific backing increase, with potential for multiple expansion.
Global gelatin and collagen capacity expansion and new rendering and biogas plants are planned to support continued growth.
Financial outlook and capital allocation
Net debt targeted below $3 billion and leverage below 2x by end of 2026, with strong cash generation expected.
Capital allocation priorities include debt reduction, potential share buybacks, and consideration of a dividend program.
Free cash flow of $4–6 billion projected through 2030, with core business now able to sustain maintenance and growth capital.
Large M&A is paused, but organic growth and selective investments in capacity and innovation will continue.
SAF business expansion is on hold pending clearer consumer demand, but remains a strategic option.
Latest events from Darling Ingredients
- Q2 2026 delivered record net income, EBITDA, and debt reduction on strong segment results.DAR
Q2 2026 - All director nominees, auditor ratification, and key compensation plans were approved.DAR
AGM 2026 - Accelerated growth, strong cash flow, and innovation in collagen set the stage for robust expansion.DAR
21st Annual Global Farm to Market Conference - Global scale, strong cash flow, and innovation in renewables and collagen drive profitable growth.DAR
Investor Day 2026 - Net income hit $134.3 million and Adjusted EBITDA more than doubled year-over-year.DAR
Q1 2026 - Shareholders will vote on directors, auditor, executive pay, and a new incentive plan amid strong 2025 results.DAR
Proxy filing - Q4/FY2025 sales and margins rose, but net income fell sharply on restructuring charges.DAR
Q4 2025 - Feed and Food drove margin gains, but Fuel/DGD losses and policy risks weighed on results.DAR
Q3 2025 - Q3 2024 net income fell to $16.9M; 2024 EBITDA guidance is $1.15–$1.175B, 2025 to exceed $1.5B.DAR
Q3 2024